AYTU:NSD-Aytu Biopharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.13

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Volume

0.66M

Avg Analyst Target

USD 11.00 (+251.44%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado. Address: 373 Inverness Parkway, Englewood, CO, United States, 80112

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD173.59B 50.81 42.70
BNTX BioNTech SE

N/A

USD87.11B 19.76 15.10
REGN Regeneron Pharmaceuticals Inc

N/A

USD69.72B 11.77 9.07
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD48.85B 24.83 16.64
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD37.67B N/A N/A
SGEN Seagen Inc

N/A

USD28.42B 48.74 37.66
GMAB Genmab A/S

N/A

USD27.66B 70.01 8.47
RPRX Royalty Pharma plc

N/A

USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

N/A

USD22.62B N/A N/A

ETFs Containing AYTU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.66% 12% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.66% 12% F 7% F
Trailing 12 Months  
Capital Gain -77.32% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.32% 3% F 1% F
Trailing 5 Years  
Capital Gain -99.76% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.76% 2% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -28.91% 6% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.91% 6% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 65.39% 47% F 27% F
Risk Adjusted Return -44.21% 15% F 6% F
Market Capitalization 0.09B 16% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.10 80% B- 93% A
Price/Book Ratio 0.60 99% A+ 97% A+
Price / Cash Flow Ratio -3.04 24% F 60% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -37.09% 71% C- 33% F
Return on Invested Capital -36.48% 63% D 21% F
Return on Assets -8.77% 86% B 29% F
Debt to Equity Ratio 11.76% 53% F 69% D+
Technical Ratios  
Short Ratio 5.59 44% F 30% F
Short Percent 8.08% 34% F 22% F
Beta -0.27 97% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.